Growth Metrics

AbCellera Biologics (ABCL) Gross Profit (2020 - 2025)

AbCellera Biologics filings provide 6 years of Gross Profit readings, the most recent being $6.0 million for Q3 2025.

  • Quarterly Gross Profit rose 79.39% to $6.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $36.2 million through Sep 2025, up 5.22% year-over-year, with the annual reading at $28.8 million for FY2024, 24.17% down from the prior year.
  • Gross Profit hit $6.0 million in Q3 2025 for AbCellera Biologics, down from $14.1 million in the prior quarter.
  • Across five years, Gross Profit topped out at $272.0 million in Q1 2022 and bottomed at $1.4 million in Q1 2025.
  • Average Gross Profit over 5 years is $49.6 million, with a median of $14.1 million recorded in 2025.
  • The largest annual shift saw Gross Profit surged 4643.2% in 2021 before it crashed 96.9% in 2023.
  • AbCellera Biologics' Gross Profit stood at $137.5 million in 2021, then crashed by 45.33% to $75.2 million in 2022, then tumbled by 73.05% to $20.3 million in 2023, then fell by 27.51% to $14.7 million in 2024, then crashed by 58.81% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Gross Profit are $6.0 million (Q3 2025), $14.1 million (Q2 2025), and $1.4 million (Q1 2025).